2018
Fabíola Leite Gouveia, Roberto Fernandes costa and Telma Maria Araújo Moura Lemos
Abstract
Polycystic ovarian syndrome (PCOS) is the most common endocrinopathy in the reproductive phase of women, with a prevalence ranging from 2.2% to 26%. In addition to hormonal and reproductive changes, it is common in PCOS to have risk factors for cardiovascular disease.
Coenzyme Q10 is a benzoquinone used in glucose and lipid metabolism, being deficient in cases of Metabolic Syndrome when untreated and in most endocrine pathologies. In addition, coenzyme Q10 plays an important role in eliminating free radicals and in inhibiting lipid and protein oxidation, with a powerful antioxidant action.
The search included the databases PubMed, Lilacs and SciELO, independent of language and publication date until 2014 September, besides reviewing the references that included studies randomized controlled. Out of the 6 eligible articles, 3 were included in the studies were published between 1934 and 2018. In total, 253 subjects participated in the included studies, with variability of 10 days to 12 months.
From 3 studies 2 evaluated the effect of coenzyme q10 supplementation on glucose metabolism, lipid metabolism and expression of metabolic and inflammatory markers, and the other study on ovulation induction. After 12 weeks two studies evaluated the effect of supplementation on metabolic markers and beneficial effects on glucose metabolism, total cholesterol and LDL and a significant improvement in the expression of biochemical and inflammatory markers were observed, and the other study improved ovulation in these women.
The results indicate that supplementation with coenzyme q10 in women with polycystic ovary syndrome is an excellent alternative to improve their metabolism.
